CHATS: Central Hypothyroidism And Adjusted Thyroxine Dose Study (Chats): Impact Of Increasing Free Thyroxine Levels In Patients With Hypopituitarism

Submission date 29/09/2006	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 29/09/2006	Overall study status Completed	 Statistical analysis plan [X] Results
Last Edited 17/01/2012	Condition category Nutritional, Metabolic, Endocrine	Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name

Prof S M Shalet

Contact details

Endocrinology Christie Hospital NHS Trust Wilsmlow Road Withington Manchester United Kingdom M20 4BX +44 0161 446 3667 stephen.m.shalet@man.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N0063173623

Study information

Scientific Title

Study objectives Primary objective of the study: impact of increased thyroxine supplementation on quality of life.

Ethics approval required Old ethics approval format

Ethics approval(s) Not provided at time of registration

Study design Randomised, double-blind, placebo-controlled study

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Not specified

Study type(s) Quality of life

Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied Nutritional, Metabolic, Endocrine: Hypopituitarism

Interventions Arm A: Thryoxine Arm B: Placebo

Intervention Type Drug

Phase Not Specified

Drug/device/biological/vaccine name(s)

Thryoxine

Primary outcome measure

QoL assessment with: 1. PGWB (Psychological General Well-Being Schedule) 2. SF-36 (Medical Outcomes Study Short Form36) 3. EQ-5D (EuroQol EQ-5D) and questionnaires

Secondary outcome measures

Thyroid-specific symptom questionnaire
 QoL assessment with QoL-AGHDA
 BP, HR
 fT4, fT3, TSH
 CK, SHBG
 Fasting TC, LDL-C, HDL-C, Lp(a)
 Body composition, BMI
 ECG and 24 hour Holter ECG
 Carotid intima-media thickness measurement

Overall study start date

23/09/2005

Completion date 31/12/2008

Eligibility

Key inclusion criteria Patients (aged 20-70) with hypopituitarism and low-normal free thyroxine levels.

Participant type(s) Patient

Age group Adult

Sex Not Specified

Target number of participants

A total of 80 patients are required for the trial.

Key exclusion criteria

- 1. Age <20 or >70 years
- 2. Inability to give informed consent
- 3. Obvious or suspected poor compliance
- 4. Thyrotoxicosis
- 5. Severe concomitant illness with significant impact on life expectancy
- 6. Active acromegaly or Cushing's disease

7. Uncontrolled cardiac arrhythmias or unstable ischaemic heart disease
 8. Treatment with Amiodarone or Lithium within the last 6 months
 9. Current treatment with: L-Tri-iodothyronine, Carbimazole, Propylthiouracil

Date of first enrolment 23/09/2005

Date of final enrolment 31/12/2008

Locations

Countries of recruitment England

United Kingdom

Study participating centre Endocrinology Manchester United Kingdom M20 4BX

Sponsor information

Organisation Record Provided by the NHSTCT Register - 2006 Update - Department of Health

Sponsor details The Department of Health, Richmond House, 79 Whitehall London United Kingdom SW1A 2NL +44 (0)20 7307 2622 dhmail@doh.gsi.org.uk

Sponsor type Government

Website http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type Government

Funder Name Christie Hospital NHS Trust

Funder Name NHS R&D Support Funding

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

01/01/2007

IPD sharing plan summary

Results article

Not provided at time of registration

Study outputs					
Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Deculto acticle	results	01/01/2007		Vac	Ne

Yes

No